Evidence map›Paper›PMID 41617243›Full record

ArticleBMJ open2026

Country-level and global burden of diseases caused by group A

Belaynew Wasie Taye, Jeffrey Cannon, Chris Van Beneden, Asha C Bowen, Mark Engel, Michael George Baker, Rebecca L Guy, Theresa Lamagni, Jonathan Carapetis, Hannah C Moore and 1 more

Abstract read
In one paragraph

Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Belaynew Wasie TayeWesfarmers Centre of Vaccines and Infectious DIseases, The Kids Research Institute Australia, University of Western Australia, Perth, Western Australia, Australia belaynew.taye@thekids.org.au.ORCID http://orcid.org/0000-0003-2659-1059
Jeffrey CannonWesfarmers Centre of Vaccines and Infectious DIseases, The Kids Research Institute Australia, University of Western Australia, Perth, Western Australia, Australia.
Chris Van BenedenMedical Epidemiologist, Consultant, Atlanta, Georgia, USA.
Asha C BowenSchool of Medicine, University of Western Australia, Perth, Western Australia, Australia.
Mark EngelDivision of Cardiology, Department of Medicine, University of Cape Town, Cape Town, South Africa.ORCID http://orcid.org/0000-0002-1334-8829
Michael George BakerDepartment of Public Health, University of Otago, Wellington, New Zealand.
Rebecca L GuyNational Infection Service, UK Health Security Agency, London, UK.
Theresa LamagniNational Infection Service, UK Health Security Agency, London, UK.
Jonathan CarapetisSchool of Medicine, University of Western Australia, Perth, Western Australia, Australia.
Hannah C MooreWesfarmers Centre of Vaccines and Infectious DIseases, The Kids Research Institute Australia, University of Western Australia, Perth, Western Australia, Australia.
Strep A Vaccine Global Consortium (SAVAC) 2.0

Funding

Wellcome Trust
6 · The paper itself

Abstract

introductionGroup A METHODS AND ANALYSIS: This population-based descriptive study will use routine health data obtained from different low-income and middle-income and high-income countries through international research collaborations to estimate the country-level and global burden of Strep A diseases. Data will be primarily obtained and collated from hospital or national health laboratory databases for individuals across all age groups, along with emergency department, primary care and microbiological datasets where available. Strep A disease endpoints will be identified using International Classification of Diseases 10th Revision or other relevant coding systems and microbiological diagnosis. Age-specific incidence and prevalence rates will be computed using population denominators, and country-level age-adjusted rates will be applied to standard global reference populations to estimate the number of cases globally. ETHICS AND DISSEMINATION: Ethical approval to conduct this study was obtained from the Human Research Ethics Committee at the University of Western Australia (reference: #2024/ET000401) and governance approval was obtained from The Kids Research Institute Australia. The findings from this study will be published in peer-reviewed journals and presented at Strep A Vaccine Global Consortium collaborative meetings.

Indexed as

Streptococcal InfectionsStreptococcus pyogenesChildGlobal Burden of DiseaseGlobal HealthHumansIncidencePrevalenceCardiovascular DiseaseEPIDEMIOLOGYINFECTIOUS DISEASES

Identifiers

PMID41617243
PMCPMC12863330

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.